ALISO VIEJO, Calif., Nov. 12, 2019 /PRNewswire/ -- Avanir Pharmaceuticals, Inc., a pharmaceutical company committed to delivering innovative central nervous system (CNS) solutions to improve the lives of patients and their care communities, announced today that it will continue the clinical development program of AVP-786 (deudextromethorphan hydrobromide [d6-DM]/quinidine sulfate [Q]) for the treatment of agitation in patients with Alzheimer's dementia. The decision is based on insights derived from detailed analysis of data from the first and second phase 3 AVP-786 clinical trials. Preliminary results of the first and second phase 3 clinical trials (15-AVP-786-301 and 15-AVP-786-302) were released March 25 and September 27, 2019, respectively.
Otsuka’s Avanir unit has been dealt yet another setback after its second phase 3 trial of its new drug for agitation in Alzheimer’s disease missed the mark.